Christopher Loose

Christopher Loose is the co-founder and CEO of Progentos Therapeutics, developing restorative therapies for multiple sclerosis. He serves as the Executive Director of Yale University’s Center for Biomedical and Interventional Technology and holds an academic appointment as Adjunct Associate Professor of Urology at the Yale School of Medicine.

Education:

• Ph.D., Chemical Engineering, Massachusetts Institute of Technology (MIT)
• B.S.E., Chemical Engineering (Summa Cum Laude), Princeton University

Dr. Loose’s research focuses on biotechnology and regenerative medicine, particularly platform technologies for addressing unmet clinical needs. His work spans medical device innovations (e.g., antimicrobial surface modifications at Semprus BioSciences) and regenerative therapies for hearing loss (via Frequency Therapeutics) and multiple sclerosis (via Progentos Therapeutics).

Scientific Awards:

• Peter Strauss Entrepreneurial Award (2011)
• MIT Technology Review 35 Innovators Under 35 (2007)
• Boston Business Journal 40 Under 40
• Hertz Thesis Prize (2007)

Dr. Loose co-founded MIT spin-offs Semprus BioSciences (acquired by Teleflex) and Frequency Therapeutics (IPO). He previously held leadership roles as Chief Scientific Officer (Frequency Therapeutics) and Chief Technology Officer (Semprus BioSciences). At Yale, he oversees a center dedicated to biomedical innovation.